AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions and listings of claims in this application:

1. (Currently Amended) A molecule comprising the antigen-binding portion of an isolated antibody which has an increased affinity for a fibroblast growth factor receptor 3 (FGFR3) and which blocks activation of said fibroblast growth factor receptor FGFR3.

Claims 2-5. (Cancelled)

- 6. (Currently Amended) The molecule according to claim 1, wherein said molecule blocks constitutive activation of said FGFR3fibroblast growth factor receptor.
- 7. (Previously Presented) The molecule according to claim 6, comprising a V_H region and a V_L region, respectively, selected from SEQ ID NO: 96 and SEQ ID NO: 85; SEQ ID NO: 98 and SEQ ID NO: 87; and SEQ ID NO: 106 and SEQ ID NO: 95.
- 8. (Previously Presented) The molecule according to claim 6, comprising a V_{H^-} CDR3 region and a V_{L^-} CDR3 region, respectively, selected from SEQ ID NO: 8 and SEQ ID NO: 9; SEQ ID NO: 12 and SEQ ID NO:13; and SEQ ID NO: 24 and SEQ ID NO:25.
- 9. (Original) The molecule according to claim 8, comprising a V_H -CDR3 region and a V_L -CDR3 region having SEQ ID NO:24 and SEQ ID NO:25, respectively.
- 10. (Previously Presented) A pharmaceutical composition, comprising as an active ingredient at least one molecule according to claim 6 and a pharmaceutically acceptable carrier, excipient, or auxiliary agent.

Claims 11-14. (Cancelled)

15. (Currently Amended) A molecule according to claim 1 wherein said molecule comprising the antigen-binding portion of an antibody which binds to a fibroblast growth factor receptor (FGFR) and which-blocks ligand-dependent activation of the said FGFR3.

Claims 16-17. (Cancelled)

18. (Previously Presented) The molecule according to claim 15, comprising a V_H region and a V_L region, respectively, selected from SEQ ID NO: 97 and SEQ ID NO: 86; SEQ ID NO: 99 and SEQ ID NO: 88; SEQ ID NO: 100 and SEQ ID NO: 89; SEQ ID NO: 101 and SEQ ID NO: 90; SEQ ID NO: 102 and SEQ ID NO: 91; SEQ ID NO: 103 and SEQ ID NO: 92; SEQ ID NO: 104 and SEQ ID NO: 93 and SEQ ID NO: 105 and SEQ ID NO: 94.

Claim 19. (Cancelled)

20. (Original) The molecule according to claim 15, comprising a V_H -CDR3 region and a V_L -CDR3 region selected from SEQ ID NO:10 and SEQ ID NO:11; SEQ ID NO:14 and SEQ ID NO:15; SEQ ID NO:16 and SEQ ID NO:17; SEQ ID NO:18 and SEQ ID NO:19; SEQ ID NO:20 and SEQ ID NO:21; SEQ ID NO:22 and SEQ ID NO:23; SEQ ID NO:26 and SEQ ID NO:27 and SEQ ID NO:28 and SEQ ID NO:29.

Claim 21. (Cancelled)

22. (Original) A pharmaceutical composition, comprising as an active ingredient at least one molecule according to claim 15 and a pharmaceutically acceptable carrier, excipient, or auxiliary agent.

Claims 23-30. (Cancelled)

31. (Currently Amended) A kit comprising the molecule of claim 1, or a molecule comprising the antigen-binding portion of an antibody which binds to a fibroblast growth factor receptor (FGFR) and which blocks ligand-dependent activation of the FGFR, the kit further

comprising at least one reagent suitable for detecting the presence of said molecule when bound to said <u>FGFR3</u> receptor protein tyrosine kinase and instructions for use.

- 32. (Currently Amended, Withdrawn) A method for treating or inhibiting a skeletal dysplasia or a craniosynostosis disorder, comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 10 to a subject in need thereof, wherein the pharmaceutical composition is according to claim 10 or is a pharmaceutical composition comprising as an active ingredient at least one molecule that is an antigen-binding portion of an antibody which binds to a fibroblast growth factor receptor (FGFR) and which blocks ligand dependent activation of the FGFR.
- 33. (Withdrawn) The method according to claim 32, wherein the skeletal dysplasia is selected from achondroplasia, thanatophoric dysplasia (TD), hypochondroplasia, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) dysplasia.
- 34. (Withdrawn) The method according to claim 33, wherein said skeletal dysplasia is achondroplasia.
- 35. (Withdrawn) The method according to claim 32, wherein the craniosynostosis disorder is Muenke coronal craniosynostosis or Crouzon syndrome with acanthosis nigricans.

Claims 36-37. (Cancelled)

38. (Currently Amended, Withdrawn) A method for treating or inhibiting a cell proliferative disease or disorder associated with abnormal <u>FGFR3 RPTK</u>-activity, comprising administering a therapeutically effective amount of the pharmaceutical composition <u>according to claim 10</u> to a subject in need thereof, wherein the pharmaceutical composition is according to elaim 10 or is a pharmaceutical composition comprising as an active ingredient at least one molecule that is an antigen-binding portion of an antibody which binds to a fibroblast growth factor receptor (FGFR) and which blocks ligand dependent activation of the FGFR.

- 39. (Withdrawn) The method according to claim 38, wherein the cell proliferative disease or disorder is selected from solid tumors, non-solid cancer or tumor progression,
- 40. (Withdrawn) The method according to claim 39, wherein the tumor progression is the progression of transitional cell carcinoma, mammary carcinoma, osteosarcoma or chondrosarcoma.
- 41. (Withdrawn) The method according to claim 39, wherein the non-solid cancer is a hematopoietic malignancy.
- 42. (Withdrawn) The method according to claim 41, wherein the hematopoietic malignancy is multiple myeloma.
- 43. (Currently Amended, Withdrawn) The method according to claim 38, wherein the disorder is associated with the action of a constitutively activated receptor protein tyrosine kinase or with ligand-dependent activation of a receptor protein tyrosine kinase.
- 44. (Currently Amended, Withdrawn) A method for screening a molecule comprising the antigen-binding portion of an antibody according to claim 1 which blocks ligand-independent or ligand-dependent activation of a receptor protein tyrosine kinase, comprising: providing a library of antigen binding fragments; screening a library of antigen binding fragments for binding to a dimeric form of a <u>FGFR3</u>receptor protein tyrosine kinase; identifying an antigen binding fragment which binds to the dimeric form of the <u>FGFR3</u>receptor protein tyrosine kinase as a candidate molecule for blocking-constitutive-activation of the <u>FGFR3</u>receptor protein tyrosine kinase; and determining whether the candidate molecule blocks constitutive and/or ligand-dependent activation-of <u>FGFR3</u> the receptor protein tyrosine kinase in a cell.

Claims 45-49. (Cancelled)